Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UBE2E2 divergent transcript (UBE2E2-DT) is a human long non-coding RNA (lncRNA) gene, and is affiliated with the lncRNA molecular class. It is also known as UBE2E2-AS1 and UBE2E2 antisense RNA 1 (head to head)[3]. Unlike closely related protein-coding genes such as UBE2E2, which encodes an E2 ubiquitin-conjugating enzyme, UBE2E2-DT produces a non-coding RNA molecule whose precise biological and pathological roles are not currently documented in major genetic or biomedical databases. It is classified only as an lncRNA gene, and there is no evidence of it serving as a druggable therapeutic target, disease biomarker, nor having known drug interactions or therapy-related safety concerns[3]. The gene is cataloged in the HGNC (44512), NCBI Gene (100505877), and Ensembl (ENSG00000233153) databases, highlighting its confirmed identity as a human lncRNA[3]. In summary, UBE2E2-DT is an lncRNA with no established disease roles, therapeutic targeting, or documented molecular functions, and should not be classified as a conventional drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UBE2E2 divergent transcript (UBE2E2-DT).